Touch Surgery and Pacira Pharmaceuticals (NSDQ:PCRX) launched the Exparel knee training simulation for the Touch Surgery app, designed to provide clinicians with a virtual training experience for administering the bupivacaine liposome injectable suspension in total knee arthroplasty. The simulation includes a 3D environment where clinical decisions and viewpoints are all dictated by the user and simulates […]
Pharmaceuticals
Dow subsidiary presents transdermal delivery system
Dow (NYSE:DOW) subsidiary Dow Corning presented its latest drug delivery tech for transdermal therapies at the American Assn. of Pharmaceutical Sciences annual meeting. Dow Corning introduced its transdermal delivery patch, the SilAc Hybrid pressure-sensitive adhesive, which combine the properties of acrylic and silicone polymers. The Midland, Mich.-based company also featured its silicone-based topical ingredients with enhanced […]
Trump’s win boosts drug stocks
Pharmaceutical stocks surged today after Donald Trump won the U.S. presidential election, as investors concluded the threat of action on drug pricing had lessened. California’s Proposition 61, which would have prevented the state of California from purchasing drugs from a manufacturer for a price higher than that paid by the U.S. Veterans Affairs Dept., failed to […]
Gold nanoparticles target chromosomes in cancer cells
Researchers tagged gold nanoparticles with a small dose of radiation to trace the particles as they deliver a drug into the heart of a cancer cell, according to work presented at the 2016 National Cancer Research Institute conference. A team of researchers from the Oxford Institute for Radiation Oncology worked to deliver drugs to the “control […]
Senate panel adds to call for hearings over Mylan’s EpiPen pricing
The U.S. Senate Judiciary Committee yesterday called on the Federal Trade Commission to investigate whether Mylan (NSDQ:MYL) broke the law after reports claimed the EpiPen maker prevented schools from buying competing allergy treatments. In a letter penned to the FTC, committee chairman Sen. Charles Grassley (R-Iowa) and ranking member Sen. Patrick Leahy (D-Vt.) wrote, “increasing patient access […]
Catalent tops Q1 estimates, profits fall 61%
Shares in Catalent (NYSE:CTLT) rose yesterday after the drug-delivery company met expectations on Wall Street with its fiscal 1st-quarter results. The Somerset, N.J.-based company posted profits of $4.6 million, or 4¢ per share, on sales of $442.2 million for the 3 months ended Sept. 30, for a bottom-line slide of -60.7% on sales growth of 4.5% compared with […]
Flamel Technologies tops Q3 revenue, EPS estimate
Shares in Flamel Technologies (NSDQ:FLML) rose today after the pharmaceutical company met expectations on Wall Street with its 3rd quarter results. The Venissieux, France-based company posted a loss of -$22.3 million on sales of $32.1 million for the 3 months ended Sept. 30, for bottom-line growth of 20% despite a sales loss of 32% compared with the […]
CMS acting chief Slavitt slams drug pricing
Centers for Medicare & Medicaid Services acting chief Andy Slavitt admonished pharma companies like Mylan (NSDQ:MYL) over unsustainable price increases before the Biopharma Congress in Washington D.C. last week. Mylan came under fire this year after reports showed that the Canonsburg, Penn.-based company raised the price of its emergency allergy epinephrine injector by 500% since it acquired the product in 2007 […]
UCB’s Cimzia AutoClicks pen hits the U.K. market
UCB (EBR:UCB) said today that its Cimzia AutoClicks pre-filled pen is available in the U.K., after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the device for all approved indications, including rheumatoid arthritis and axial spondyloarthritis. The Belgian company partnered with OXO to develop the pen, based on technology licensed from Bespak. The AutoClicks […]
Cerulean, Novartis ink $5m deal to co-develop nanoparticle-drug conjugates
UPDATED Oct. 20, 2016, with Cerulean share price movement. Cerulean Pharma Inc. (NSDQ:CERU) said today that it inked a deal with Novartis (NYSE:NVS) to develop nanoparticle-drug conjugates. The products will match Cerulean’s tumor-targeting tech with Novartis compounds directed at up to 5 targets. The agreement calls for Cerulean to receive $5 million plus funding for 5 full-time equivalents […]